AnaptysBio Inc宣布,在相关交易完成后,版税管理公司将负责管理其版税收入,其中包括Jemperli和Imsidolimab等产品的版税。
AnaptysBio Inc宣布,在相关交易完成后,版税管理公司将负责管理其版税收入,其中包括Jemperli和Imsidolimab等产品的版税。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.